0000000000261465

AUTHOR

Ineta Kalnina

0000-0003-3462-3196

showing 8 related works from this author

Genome-wide analysis reveals DNA methylation markers that vary with both age and obesity

2014

AbstractThe combination of the obesity epidemic and an aging population presents growing challenges for the healthcare system. Obesity and aging are major risk factors for a diverse number of diseases and it is of importance to understand their interaction and the underlying molecular mechanisms. Herein the authors examined the methylation levels of 27578 CpG sites in 46 samples from adult peripheral blood. The effect of obesity and aging was ascertained with general linear models. More than one hundred probes were correlated to aging, nine of which belonged to the KEGG group map04080. Additionally, 10 CpG sites had diverse methylation profiles in obese and lean individuals, one of which wa…

AdultGenetic Markersmedicine.medical_specialtyAgingAlpha-Ketoglutarate-Dependent Dioxygenase FTOGenome-wide association studyBiologyMicroarrayBioinformaticsEpigenesis GeneticGeneticsmedicineHumansEpigeneticsObesityKEGGTelomeraseAgedMedicinsk genetikGeneticsProteinsGeneral MedicineMethylationDNA MethylationMiddle Agedmedicine.diseaseObesityCpG siteDNA methylationMedical geneticsCpG IslandsFemaleEpigeneticsMedical GeneticsGenome-Wide Association Study
researchProduct

The evolutionary history and tissue mapping of GPR123: specific CNS expression pattern predominantly in thalamic nuclei and regions containing large …

2007

The Adhesion family of G protein-coupled receptors (GPCRs) includes 33 receptors and is the second largest GPCR family. Most of these proteins are still orphans and fairly little is known of their tissue distribution and evolutionary context. We report the evolutionary history of the Adhesion family protein GPR123 as well as mapping of GPR123 mRNA expression in mouse and rat using in situ hybridization and real-time PCR, respectively. GPR123 was found to be well conserved within the vertebrate lineage, especially within the transmembrane regions and in the distal part of the cytoplasmic tail, containing a potential PDZ binding domain. The real-time PCR data indicates that GPR123 is predomin…

Central Nervous SystemMaleModels MolecularNeuronal signal transductionPDZ domainGene ExpressionContext (language use)In situ hybridizationBiologyBiochemistryReceptors G-Protein-CoupledMiceCellular and Molecular NeuroscienceAnimalsHumansTissue DistributionRNA MessengerNeural Cell Adhesion MoleculesIn Situ HybridizationPhylogenyG protein-coupled receptorReverse Transcriptase Polymerase Chain ReactionPyramidal CellsSubiculumRatsCell biologySignal transductionSequence AlignmentNeuroscienceBinding domainJournal of Neurochemistry
researchProduct

Polymorphisms in FTO and near TMEM18 associate with type 2 diabetes and predispose to younger age at diagnosis of diabetes

2013

Variations in the FTO gene and near the TMEM18 gene are risk factors for common form of obesity, but have also been linked with type 2 diabetes (T2D). Our aim was to investigate the contribution of these variants to risk of T2D in a population in Latvia. Four single nucleotide polymorphisms (SNP) in the first and fourth intronic regions of FTO and one close to TMEM18 were genotyped in 987 patients with T2D and 1080 controls selected from the Latvian Genome Data Base (LGDB). We confirmed association of SNPs in the first intron (rs11642015, rs62048402 and rs9939609) of FTO and rs7561317 representing the TMEM18 locus with T2D. Association between SNP in FTO and T2D remained significant after c…

Linkage disequilibriumendocrine system diseasesPopulationAlpha-Ketoglutarate-Dependent Dioxygenase FTOSingle-nucleotide polymorphismLocus (genetics)Genome-wide association studyBiologyPolymorphism Single NucleotideFTO geneGeneticsmedicineHumansSNPAge of OnseteducationGeneticseducation.field_of_studyAge FactorsMembrane ProteinsProteinsnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseObesityDiabetes Mellitus Type 2Gene
researchProduct

A widely used sampling device in colorectal cancer screening programmes allows for large-scale microbiome studies.

2018

We read with interest the article by Passamonti et al ,1 reporting the performance of two different faecal immunochemical tests (FITs) highlighting the importance of standardisation and validation of screening methodologies. Conventionally, laboratory-based FIT is the preferred approach in testing for occult blood in faeces, which includes colorectal cancer screening programmes.2–4 The potential of preserving stable faecal samples in a widely used FIT buffer for microbiome research would enable prospective microbiome studies in generally healthy subjects undergoing colorectal cancer screening. For this purpose, we evaluated faecal sample stability in the commonly used OC-Sensor (Eiken Chemi…

0301 basic medicineVeterinary medicine2312BiologySampling device03 medical and health sciencesHemoglobins0302 clinical medicineHumansMass Screening1506Microbiomecolonic microfloraEarly Detection of CancerMicrobiotaGastroenterologyHealthy subjectsIllumina miseqIon semiconductor sequencingPostScriptSample stabilityGastrointestinal Microbiome030104 developmental biologyColorectal cancer screeningMetagenomicsOccult Bloodepidemiology030211 gastroenterology & hepatologyGuaiacColorectal NeoplasmsGut
researchProduct

Association of metformin administration with gut microbiome dysbiosis in healthy volunteers

2018

Background Metformin is a widely used first-line drug for treatment of type 2 diabetes. Despite its advantages, metformin has variable therapeutic effects, contraindications, and side effects. Here, for the very first time, we investigate the short-term effect of metformin on the composition of healthy human gut microbiota. Methods We used an exploratory longitudinal study design in which the first sample from an individual was the control for further samples. Eighteen healthy individuals were treated with metformin (2 × 850 mg) for 7 days. Stool samples were collected at three time points: prior to administration, 24 hours and 7 days after metformin administration. Taxonomic composition of…

0301 basic medicineMaleendocrine system diseasesPhysiologylcsh:MedicineType 2 diabetesGut floraPathology and Laboratory MedicineOpportunistic Pathogens0302 clinical medicineRNA Ribosomal 16SMedicine and Health SciencesLongitudinal Studieslcsh:ScienceData ManagementMultidisciplinarybiologydigestive oral and skin physiologyHigh-Throughput Nucleotide SequencingGenomicsHealthy VolunteersMetformin3. Good healthMetforminBacterial PathogensTolerabilityMedical MicrobiologyFemalePathogensmedicine.drugResearch ArticleMicrobial TaxonomyAdultDNA BacterialEscherichiaComputer and Information SciencesClostridiaceae030209 endocrinology & metabolismMicrobial GenomicsPlaceboDNA RibosomalMicrobiologyDrug Administration Schedule03 medical and health sciencesYoung AdultEnterobacteriaceaeAdverse ReactionsmedicineGeneticsHumansMicrobiomeMicrobial PathogensTaxonomyPharmacologyClostridiumBacteriabusiness.industryPeptostreptococcusTherapeutic effectlcsh:RGut BacteriaOrganismsBiology and Life SciencesSequence Analysis DNAmedicine.diseasebiology.organism_classificationGastrointestinal Microbiome030104 developmental biologyDysbiosislcsh:QMicrobiomebusinessDysbiosisPLOS ONE
researchProduct

Whole-blood transcriptome profiling reveals signatures of metformin and its therapeutic response

2020

Metformin, a biguanide agent, is the first-line treatment for type 2 diabetes mellitus due to its glucose-lowering effect. Despite its wide application in the treatment of multiple health conditions, the glycemic response to metformin is highly variable, emphasizing the need for reliable biomarkers. We chose the RNA-Seq-based comparative transcriptomics approach to evaluate the systemic effect of metformin and highlight potential predictive biomarkers of metformin response in drug-naive volunteers with type 2 diabetes in vivo. The longitudinal blood-derived transcriptome analysis revealed metformin-induced differential expression of novel and previously described genes involved in cholester…

0301 basic medicineMaleendocrine system diseasesMolecular biologyGene ExpressionType 2 diabetesPharmacologyBiochemistryTranscriptome0302 clinical medicineEndocrinologyMedical ConditionsSequencing techniquesGastrointestinal CancersBreast TumorsMedicine and Health SciencesHomeostasisEnergy-Producing OrganellesWhole bloodMultidisciplinarySmall nuclear RNABiguanideQRRNA sequencingGenomicsMiddle AgedMetforminMetforminMitochondriaType 2 DiabetesNucleic acidsCholesterolSmall nucleolar RNAOncology030220 oncology & carcinogenesisMedicineFemaleCellular Structures and OrganellesTranscriptome Analysismedicine.drugResearch Articlemedicine.drug_classEndocrine DisordersScienceGastroenterology and HepatologyBioenergetics03 medical and health sciencesBreast CancermedicineGeneticsDiabetes MellitusHumansNon-coding RNAGlycemicAgedbusiness.industryGene Expression ProfilingType 2 Diabetes Mellitusnutritional and metabolic diseasesBiology and Life SciencesComputational BiologyCancers and NeoplasmsCell Biologymedicine.diseaseGenome AnalysisGene regulationGene expression profilingResearch and analysis methods030104 developmental biologyMolecular biology techniquesMetabolic DisordersRNAbusinessBlood Chemical AnalysisPLoS ONE
researchProduct

Baseline gut microbiome composition predicts metformin therapy short-term efficacy in newly diagnosed type 2 diabetes patients

2020

BackgroundThe study was conducted to investigate the effects of metformin treatment on the human gut microbiome's taxonomic and functional profile in the Latvian population, and to evaluate the correlation of these changes with therapeutic efficacy and tolerance.MethodsIn this longitudinal observational study, stool samples for shotgun metagenomic sequencing-based analysis were collected in two cohorts. The first cohort included 35 healthy nondiabetic individuals (metformin dose 2x850mg/day) at three time-points during metformin administration. The second cohort was composed of 50 newly-diagnosed type 2 diabetes patients (metformin dose-determined by an endocrinologist) at two concordant ti…

AdultMale0301 basic medicinemedicine.medical_specialtyendocrine system diseasesSciencePopulationPrevotella030209 endocrinology & metabolismType 2 diabetesGastroenterologyYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineHumansMedicineLongitudinal StudiesMicrobiomeeducationeducation.field_of_studyMultidisciplinarybiologyBacteroidetesbusiness.industryMicrobiotaQTherapeutic effectRnutritional and metabolic diseasesmedicine.diseasebiology.organism_classificationMetforminGastrointestinal MicrobiomeMetforminLactococcus lactis030104 developmental biologyDiabetes Mellitus Type 2CohortMedicineDialisterFemalebusinessResearch Articlemedicine.drugEnterococcus faeciumPLOS ONE
researchProduct

Stronger Association of Common Variants in TCF7L2 Gene with Nonobese Type 2 Diabetes in the Latvian Population

2012

Polymorphisms in the gene coding for transcription factor 7 like 2 (TCF7L2) are recognized as the strongest common genetic risk factors for type 2 diabetes (T2D) across multiple ethnicities. This study was conducted to evaluate an association between TCF7L2 variants and diabetes susceptibility in the population of Latvia. We genotyped 4 single nucleotide polymorphisms (SNP) rs7901695, rs7903146, rs11196205 and rs12255372 in 1 093 controls and 1 043 diabetic subjects. Association with T2D was found for 3 SNPs rs7901695, rs7903146 and rs12255372 in the whole sample (under an additive genetic model, the adjusted odds ratios (OR) were 1.26, 95% CI [1.08-1.48], P=0.003; OR=1.32, 95% CI [1.12-1.5…

Maleendocrine systemendocrine system diseasesEndocrinology Diabetes and MetabolismPopulationSingle-nucleotide polymorphismType 2 diabetesBiologyPolymorphism Single NucleotideBody Mass IndexEndocrinologyPolymorphism (computer science)Databases GeneticGenetic modelInternal MedicinemedicineHumansSNPGenetic Predisposition to DiseaseObesityeducationGenetic Association StudiesGeneticseducation.field_of_studynutritional and metabolic diseasesGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseLatviaDiabetes Mellitus Type 2Case-Control StudiesFemaleTranscription Factor 7-Like 2 ProteinTCF7L2Experimental and Clinical Endocrinology & Diabetes
researchProduct